Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial

被引:11
作者
Shimada, Hitoshi [1 ]
Nilsson, Catarina [2 ]
Noda, Yoshinori [1 ]
Kim, Hyosung [1 ]
Lundstrom, Torbjorn [2 ]
Yajima, Toshitaka [3 ]
机构
[1] AstraZeneca KK, Osaka, Japan
[2] AstraZeneca Gothenburg, Molndal, Sweden
[3] AstraZeneca KK, Tokyo, Japan
关键词
Omega-3 fatty acids; Eicosapentaenoic acid; Docosahexaenoic acid; Pharmacokinetics; Japan; CORONARY-ARTERY-DISEASE; LOW-FAT DIET; EICOSAPENTAENOIC ACID; SEVERE HYPERTRIGLYCERIDEMIA; ENDOTHELIAL FUNCTION; DIABETES-MELLITUS; OMEGA-3; BIOAVAILABILITY; FORMULATION; PREVENTION;
D O I
10.5551/jat.38737
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aims: Omega-3-carboxylic acids (OM3-CA) contain omega-3 free fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as carboxylic acids. Food intake is known to affect the bioavailability of ethyl ester fatty acid formulations. We conducted a phase I study to investigate the effects of the timing of OM3-CA administration relative to food intake on the pharmacokinetics of EPA and DHA. Methods: In this randomized, open-label, three-period crossover study, Japanese healthy male subjects were administered 4 x 1 g OM3-CA capsules with continued fasting, before a meal, or after a meal. All subjects fasted for >= 10 h prior to drug/meal administration. The primary objective was to examine the effect of meal timing on the pharmacokinetics of EPA and DHA after OM3-CA administration. The secondary objectives were to examine the safety and tolerability of OM3-CA. Results: A total of 42 Japanese subjects was enrolled in the study. The baseline-adjusted maximum concentration and area under the concentration-time curve from 0 to 72 h for EPA, DHA, and EPA + DHA were lower in the fasting and before meal conditions than in the after meal condition. The maximum total EPA, total DHA, and total EPA + DHA concentrations were reached later when administered in fasting conditions than in fed conditions, indicating slower absorption in fasting conditions. Diarrhea was reported by five, six, and no subjects in the fasting, before meal, and after meal conditions, respectively. Conclusions: The timing of OM3-CA administration relative to food intake influences the systemic bioavailability of EPA and DHA in healthy Japanese male subjects.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 15 条
[1]  
AstraZeneca Pharmaceuticals LP, 2014, OM 3 FREE FATT AC EP
[2]   Omega-3 Carboxylic Acids (Epanova®): A Review of Its Use in Patients with Severe Hypertriglyceridemia [J].
Blair, Hannah A. ;
Dhillon, Sohita .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (05) :393-400
[3]   A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study [J].
Davidson, Michael H. ;
Johnson, Judith ;
Rooney, Michael W. ;
Kyle, Michael L. ;
Kling, Douglas F. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (06) :573-584
[4]   Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial [J].
Kastelein, John J. P. ;
Maki, Kevin C. ;
Susekov, Andrey ;
Ezhov, Marat ;
Nordestgaard, Borge G. ;
Machielse, Ben N. ;
Kling, Douglas ;
Davidson, Michael H. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (01) :94-106
[5]   Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease - Secondary Prevention Analysis From JELIS [J].
Matsuzaki, Masunori ;
Yokoyama, Mitsuhiro ;
Saito, Yasushi ;
Origasa, Hideki ;
Ishikawa, Yuichi ;
Oikawa, Shinichi ;
Sasaki, Jun ;
Hishida, Hitoshi ;
Itakura, Hiroshige ;
Kita, Toru ;
Kitabatake, Akira ;
Nakaya, Noriaki ;
Sakata, Toshiie ;
Shimada, Kazuyuki ;
Shirato, Kunio ;
Matsuzawa, Yuji .
CIRCULATION JOURNAL, 2009, 73 (07) :1283-1290
[6]  
Nakamura N, 1998, IN VIVO, V12, P311
[7]   Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus [J].
Nomura, S ;
Kanazawa, S ;
Fukuhara, S .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (03) :153-159
[8]   Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study [J].
Offman, Elliot ;
Marenco, Ted ;
Ferber, Sandy ;
Johnson, Judith ;
Kling, Douglas ;
Curcio, Danielle ;
Davidson, Michael .
VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 :563-573
[9]   Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability [J].
Okumura, T ;
Fujioka, Y ;
Morimoto, S ;
Tsuboi, S ;
Masai, M ;
Tsujino, T ;
Ohyanagi, M ;
Iwasaki, T .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2002, 324 (05) :247-253
[10]   Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome [J].
Satoh, Noriko ;
Shimatsu, Akira ;
Kotani, Kazuhiko ;
Himeno, Akihiro ;
Majima, Takafumi ;
Yamada, Kazunori ;
Suganami, Takayoshi ;
Ogawa, Yoshihiro .
HYPERTENSION RESEARCH, 2009, 32 (11) :1004-1008